12:00 AM
 | 
Mar 18, 2013
 |  BC Week In Review  |  Clinical News  |  Preclinical Results

Zyngenia preclinical data

In a mouse xenograft model of pancreatic cancer, Zyngenia's cetuximab-based bispecific zybody targeting EGFR and epidermal growth factor receptor 3 ( EGFR3; HER3; ...

Read the full 135 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >